Molecular genetic basis of malignant tumor heterogeneity

V F Semiglazov; E N Imyanitov; G A Dashyan; V St Semiglazov; E D Mazcko; V G Ivanov; A A Bojok; R M Paltyev; D A Voskresenskiy; E A Shamina

Medical academic journal ›› 2009, Vol. 9 ›› Issue (4) : 37 -40.

Articles

research-article

Molecular genetic basis of malignant tumor heterogeneity

Author information +

History +

Abstract

Molecular heterogeneity of oncological diseases is revealed to the greatest extent in the case of leucosis (the discovery of «Philadelphia chromosome», i.e. translocation between the 9th and 22nd chromosome). Molecular analysis has allowed defining several subtypes of breast cancer: (i) luminal A (clearly hormone-sensitive), (ii) luminal В (relatively hormone-sensitive), (iii) breast cancer with an upregulation of HER2/neu, (iv) basal-like cancer (frequent in patients with BRCA1 mutation and without HER 2, ER and PR expression). Molecular genetic cancer subtypes differ in their prognosis and responsiveness to various therapies. Many of the discovered growth factors have proved to be targets for successful therapy.

Keywords

cancer / molecular heterogeneity / target therapy

Cite this article

Download citation ▾

V F Semiglazov, E N Imyanitov, G A Dashyan, V St Semiglazov, E D Mazcko, V G Ivanov, A A Bojok, R M Paltyev, D A Voskresenskiy, E A Shamina. Molecular genetic basis of malignant tumor heterogeneity. Medical academic journal, 2009, 9(4): 37-40 DOI:

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неоадъювантное и адъювантное лечение рака молочной железы. МИА, 2008. 288 с.

[2]	Abd El-Rehim D.M., Pinder S.E., Paish C.E. et al. Expression of luminal and basal cytokeratins in human breast carcinoma // J. Pathol. 2004. Vol. 203. P. 661-671.

[3]	Callagy G, Cattaneo E., Daigo Y. et al. Molecular classification of breast carcinomas using tissue microarrays // Diagn. Mol. Pathol. 2003. Vol. 12. P. 27-34.

[4]	Gora-Tybor J., Robak T. Targeted drugs in chronic myeloid leukemia // Cur. Med. Chem. 2008. Vol. 15 (29). P. 3036-3051.

[5]	Jacquemier J., Ginestier C, Rougemont J. et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis // Cancer Res. 2005. Vol. 65. P. 767-779.

[6]	Nielsen Т.О., Hsu F.D., Jensen K. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma // Clin. Cancer Res. 2004. Vol. 10. P. 5367-5374.

[7]	Ogino S., Goel A. Molecular classification and correlates in colorectal cancer // J. Mol. Diagn. 2008 (Jan), i Vol. 10(1). P. 13-27.

[8]	Perou СМ., Sorlie Т., Eisen M.B. et al. Molecular portraits of human breast tumors // Nature. 2000. Vol. 406. P. 747-752.

[9]	Sorlie Т., Perou СМ., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 10869-10874.

[10]	Sorlie Т., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 8418-8423.

[11]	Sorlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities // Eur. J. Cancer. 2004. Vol. 40. P. 2667-2675.

[12]	Sotiriou C, Neo S.Y, McShane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 1039310398.

[13]	Weigelt В., Glas A.M., Wessels L.F. et al. Gene expression profiles of primary breast tumors maintained in distant metastases // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 15901-15905.